SEC Form 4 · accession 0001140361-18-002445
Loxo Oncology, Inc. · LOXO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacob Van Naarden
Officer — Chief Business Officer
Period of report
Jan 16, 2018
Accepted (ET)
Jan 18, 2018 · 5:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 16, 2018 | M | 1,541 | $3.648 | A | 1,541 | D | |
| Common StockF2,F3 | Jan 16, 2018 | S | 641 | $86.5316 | D | 900 | D | |
| Common StockF2,F4 | Jan 16, 2018 | S | 200 | $87.095 | D | 700 | D | |
| Common Stock | Jan 16, 2018 | S | 100 | $88.36 | D | 600 | D | |
| Common StockF2,F5 | Jan 16, 2018 | S | 500 | $90.07 | D | 100 | D | |
| Common Stock | Jan 16, 2018 | S | 100 | $90.45 | D | 0 | D | |
| Common Stock | Jan 17, 2018 | M | 1,541 | $3.648 | A | 1,541 | D | |
| Common StockF2,F6 | Jan 17, 2018 | S | 446 | $86.2953 | D | 1,095 | D | |
| Common StockF2,F7 | Jan 17, 2018 | S | 200 | $87.96 | D | 895 | D | |
| Common StockF2,F8 | Jan 17, 2018 | S | 695 | $89.2259 | D | 200 | D | |
| Common StockF2,F9 | Jan 17, 2018 | S | 200 | $89.865 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F10 | $3.648 | Jan 16, 2018 | M | 1,541 | D | — | Jun 18, 2024 | Common Stock | 1,541 | 112,002 | D |
| Employee Stock Option (right to buy)F10 | $3.648 | Jan 17, 2018 | M | 1,541 | D | — | Jun 18, 2024 | Common Stock | 1,541 | 110,461 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F10The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- F2Represents the aggregate of sales effected on the same day at different prices.
- F3Represents the weighted average sales price per share. The shares sold at prices ranging from $86.05 to $87.04 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F4Represents the weighted average sales price per share. The shares sold at prices ranging from $87.05 to $87.14 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F5Represents the weighted average sales price per share. The shares sold at prices ranging from $89.45 to $90.40 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F6Represents the weighted average sales price per share. The shares sold at prices ranging from $86.03 to $86.94 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F7Represents the weighted average sales price per share. The shares sold at prices ranging from $87.48 to $88.44 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F8Represents the weighted average sales price per share. The shares sold at prices ranging from $88.74 to $89.70 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F9Represents the weighted average sales price per share. The shares sold at prices ranging from $89.82 to $89.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.